Go Pro

Alnylam Pharmaceuticals (ALNY) Short Interest Ratio & Short Volume

Alnylam Pharmaceuticals logo
$288.06 -10.70 (-3.58%)
Closing price 07/13/2026 04:00 PM Eastern
Extended Trading
$287.19 -0.87 (-0.30%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals Short Interest Overview

As of June 30, 2026, Alnylam Pharmaceuticals (ALNY) had a short interest of 5.80 million shares sold short, representing 4.38% of the public float. This marks a 6.67% increase in short interest since the prior report. The short interest ratio (days to cover) is 4.2, meaning it would take 4.2 days of the average trading volume of 1.42 million shares to cover all short positions.

Current Short Interest
5,799,788 shares
Previous Short Interest
5,437,337 shares
Change Vs. Previous Month
6.67%
Dollar Volume Sold Short
$1.75 billion
Short Interest Ratio
4.2 Days to Cover
Last Record Date
June 30, 2026
Outstanding Shares
133,510,000 shares
Short Percent of Float
4.38%
Today's Trading Volume
2,682,119 shares
Average Trading Volume
1,420,110 shares
Today's Volume Vs. Average
189%
Short Selling Alnylam Pharmaceuticals?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History

ALNY Short Interest Over Time

ALNY Days to Cover Over Time

ALNY Percentage of Float Shorted Over Time

Alnylam Pharmaceuticals Tesla Short Interest History & Recent Changes

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
6/30/20265,799,788 shares $1.75 billion +6.7%4.4%4.22 $301.03
6/15/20265,437,337 shares $1.56 billion +2.6%4.1%4.76 $287.80
5/29/20265,300,015 shares $1.60 billion -1.8%4.0%5.78 $301.98
5/15/20265,398,804 shares $1.55 billion +13.1%4.1%5.13 $286.98
4/30/20264,773,214 shares $1.48 billion -5.2%3.6%4.02 $309.49
4/15/20265,034,063 shares $1.68 billion -0.4%3.8%5.12 $333.39
3/31/20265,056,408 shares $1.67 billion +15.7%3.8%4.01 $330.71
3/13/20264,369,615 shares $1.37 billion -4.4%3.3%4.18 $313.41
2/27/20264,572,652 shares $1.52 billion -12.8%3.5%4.46 $332.92
2/13/20265,244,475 shares $1.65 billion -0.7%4.0%2.8 $314.40
1/30/20265,282,136 shares $1.79 billion -5.1%4.0%3.66 $338.06
1/15/20265,565,961 shares $2.00 billion +0.6%4.3%3.72 $359.18
12/31/20255,532,159 shares $2.20 billion +32.2%4.2%2.89 $397.65
12/15/20254,184,652 shares $1.64 billion +5.7%3.2%3.19 $391.50
11/28/20253,960,190 shares $1.79 billion -7.5%3.0%4.09 $451.27
11/14/20254,279,250 shares $1.92 billion +13.5%3.3%4.49 $449.16
10/31/20253,769,098 shares $1.72 billion -5.6%2.9%3.34 $456.04
10/15/20253,990,000 shares $1.88 billion +13.7%3.1%3.4 $470.27
9/30/20253,510,000 shares $1.60 billion -5.7%N/A3.1 $456.00
9/15/20253,720,000 shares $1.72 billion -6.3%N/A3.3 $461.14
8/31/20253,970,000 shares $1.77 billion +15.7%3.1%3.6 $446.51
8/15/20253,430,000 shares $1.54 billion +5.9%N/A3.2 $448.91
7/31/20253,240,000 shares $1.27 billion -4.1%2.5%3.2 $392.24
7/15/20253,380,000 shares $1.05 billion +1.5%N/A3.6 $311.12
6/30/20253,330,000 shares $1.09 billion -1.5%2.6%3.4 $326.09
6/15/20253,380,000 shares $1.04 billion -2.0%2.6%3.4 $307.99
5/31/20253,450,000 shares $1.05 billion -6.3%2.7%3.3 $304.59
5/15/20253,680,000 shares $1.04 billion +16.8%2.9%3.7 $283.40
4/30/20253,150,000 shares $829.21 million +2.9%N/A3.3 $263.24
4/15/20253,060,000 shares $706.65 million +2.3%2.4%3.4 $230.93
3/31/20252,990,000 shares $807.36 million +17.7%2.3%3.5 $270.02
3/15/20252,540,000 shares $614.07 million +2.0%2.0%3.4 $241.76
2/28/20252,490,000 shares $614.41 million -22.7%2.0%3.7 $246.75
2/15/20253,220,000 shares $825.77 million +9.5%2.5%4.8 $256.45
1/31/20252,940,000 shares $797.65 million -6.7%N/A4.2 $271.31
1/15/20253,150,000 shares $790.68 million -6.0%N/A4.2 $251.01
12/31/20243,350,000 shares $788.29 million -4.0%N/A4.4 $235.31
12/15/20243,490,000 shares $856.59 million +3.0%N/A4.5 $245.44
11/30/20243,390,000 shares $857.91 million -9.4%N/A4.4 $253.07
11/15/20243,740,000 shares $880.99 million +1.1%N/A4.3 $235.56
SPCX Warning - and Worst News for Stocks in 50 Years (Ad)

Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.tc pixel

Learn how to prepare your portfolio for what's coming next
10/31/20243,700,000 shares $986.38 million -23.6%N/A4.6 $266.59
10/15/20244,840,000 shares $1.39 billion +7.3%N/A5.8 $287.36
9/30/20244,510,000 shares $1.24 billion +1.4%N/A5.5 $275.03
9/15/20244,450,000 shares $1.18 billion +18.0%N/A3.8 $265.27
8/31/20243,770,000 shares $990.34 million -16.6%N/A3.1 $262.69
8/15/20244,520,000 shares $1.19 billion +4.4%N/A4 $262.70
7/31/20244,330,000 shares $1.03 billion -3.6%N/A4 $237.46
7/15/20244,490,000 shares $1.15 billion +22.0%N/A4.5 $256.18
6/30/20243,680,000 shares $894.24 million +72.8%N/A3.9 $243.00
6/15/20242,130,000 shares $341.63 million -14.1%N/A2.6 $160.39
5/31/20242,480,000 shares $368.11 million -2.4%N/A4.4 $148.43
5/15/20242,540,000 shares $374.40 million -3.4%N/A4.3 $147.40
4/30/20242,630,000 shares $378.59 million +5.2%N/A3.2 $143.95
4/15/20242,500,000 shares $369.25 million -10.7%N/A3 $147.70
3/31/20242,800,000 shares $418.46 million +4.1%N/A3.3 $149.45
3/15/20242,690,000 shares $401.54 million -11.5%N/A3.2 $149.27
2/29/20243,040,000 shares $459.31 million -23.8%N/A3.6 $151.09
2/15/20243,990,000 shares $588.25 million -0.5%N/A5 $147.43
1/31/20244,010,000 shares $693.37 million -7.4%N/A6.5 $172.91
1/15/20244,330,000 shares $837.38 million -8.5%N/A7.4 $193.39
12/31/20234,730,000 shares $905.37 million -5.2%N/A7.6 $191.41
12/15/20234,990,000 shares $924.35 million -2.0%N/A7.8 $185.24
11/30/20235,090,000 shares $856.39 million -1.9%N/A7.6 $168.25
11/15/20235,190,000 shares $887.75 million -1.5%N/A8 $171.05
10/31/20235,270,000 shares $799.99 million -1.7%N/A8.3 $151.80
10/15/20235,360,000 shares $901.12 million +3.9%N/A8.7 $168.12
9/30/20235,160,000 shares $913.84 million +0.2%N/A8.6 $177.10
9/15/20235,150,000 shares $952.70 million -2.8%N/A9 $184.99
8/31/20235,300,000 shares $1.05 billion -1.5%N/A9.9 $197.82
8/15/20235,380,000 shares $969.10 million +1.7%N/A10.2 $180.13
7/31/20235,290,000 shares $1.03 billion +6.9%N/A9.7 $195.40
7/15/20234,950,000 shares $975.65 million -0.6%N/A8.4 $197.10
6/30/20234,980,000 shares $945.90 million +0.4%N/A8 $189.94
6/15/20234,960,000 shares $1.00 billion -1.8%N/A7.4 $202.34
5/31/20235,050,000 shares $934.30 million -1.4%N/A7 $185.01
5/15/20235,120,000 shares $1.06 billion +0.8%N/A6.3 $206.20
4/30/20235,080,000 shares $1.01 billion +2.2%N/A6.2 $199.20
4/15/20234,970,000 shares $1.01 billion -4.1%N/A6 $203.92
3/31/20235,180,000 shares $1.04 billion +5.1%N/A6.4 $200.32
3/15/20234,930,000 shares $915.75 million -8.5%N/A6.3 $185.75
2/28/20235,390,000 shares $1.03 billion +5.7%N/A7 $191.45
2/15/20235,100,000 shares $1.13 billion -4.3%N/A6.5 $222.10
1/31/20235,330,000 shares $1.21 billion -6.2%N/A7.1 $226.40
1/15/20235,680,000 shares $1.34 billion +11.2%N/A7.3 $235.53
12/30/20225,110,000 shares $1.21 billion -5.4%N/A6.2 $237.65
12/15/20225,400,000 shares $1.24 billion +8.2%N/A6.1 $229.37
11/30/20224,990,000 shares $1.10 billion -10.3%N/A5.1 $220.59
11/15/20225,560,000 shares $1.19 billion -7.8%N/A5.7 $214.29
10/31/20226,030,000 shares $1.25 billion +25.6%N/A6.1 $207.26
10/15/20224,800,000 shares $890.54 million +5.7%N/A4.2 $185.53
They told you not to miss this one (Ad)

The largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the absolute peak of the dot-com era. An MIT study found that 95% of companies investing in AI are seeing zero measurable return - yet the spending continues. OpenAI CEO Sam Altman has publicly said investors are 'overexcited' about AI. The investors who survived the dot-com crash weren't the ones who called the bottom - they were the ones who weren't fully exposed when it happened. Thor Metals Group offers a free guide on building a retirement not tied to this bet.tc pixel

Get your free guide from Thor Metals Group and protect your retirement
9/30/20224,540,000 shares $908.73 million +3.7%N/A4.2 $200.16
9/15/20224,380,000 shares $913.14 million +4.3%N/A4.2 $208.48
8/31/20224,200,000 shares $868.01 million -16.0%N/A4 $206.67
8/15/20225,000,000 shares $1.16 billion +1.4%N/A5.2 $231.01
7/31/20224,930,000 shares $700.26 million -1.2%N/A4.9 $142.04
7/15/20224,990,000 shares $725.50 million +4.2%N/A5.8 $145.39
6/30/20224,790,000 shares $698.62 million +1.1%N/A5.5 $145.85
6/15/20224,740,000 shares $642.03 million -15.7%5.0%5.4 $135.45
5/31/20225,620,000 shares $707.00 million -4.1%N/A6.8 $125.80
5/15/20225,860,000 shares $741.11 million -1.0%N/A6.7 $126.47
4/30/20225,920,000 shares $789.91 million +2.3%N/A7 $133.43
4/15/20225,790,000 shares $968.90 million +11.8%N/A7.1 $167.34
3/31/20225,180,000 shares $845.84 million +9.5%N/A6.4 $163.29
3/15/20224,730,000 shares $723.31 million +3.7%N/A5.4 $152.92
2/28/20224,560,000 shares $719.80 million +3.9%N/A5.2 $157.85
2/15/20224,390,000 shares $672.99 million +8.1%N/A5.3 $153.30
1/31/20224,060,000 shares $558.66 million +2.8%3.6%5.1 $137.60
1/15/20223,950,000 shares $586.58 million +11.9%N/A4.8 $148.50
12/31/20213,530,000 shares $598.62 million -6.1%N/A4.6 $169.58
12/15/20213,760,000 shares $718.39 million -4.8%N/A5.1 $191.06
11/30/20213,950,000 shares $726.01 million -2.5%N/A6.5 $183.80
11/15/20214,050,000 shares $701.91 million +4.9%N/A6.8 $173.31
10/29/20213,860,000 shares $615.90 million -0.5%N/A6.4 $159.56
10/15/20213,880,000 shares $809.21 million -3.2%N/A7.1 $208.56
9/30/20214,010,000 shares $757.13 million -9.3%N/A6.7 $188.81
9/15/20214,420,000 shares $828.66 million -8.5%N/A7 $187.48
8/31/20214,830,000 shares $972.91 million -3.6%N/A7.2 $201.43
8/13/20215,010,000 shares $984.67 million -1.0%N/A7.3 $196.54
7/30/20215,060,000 shares $905.44 million +19.9%N/A7.7 $178.94
7/15/20214,220,000 shares $725.63 million -2.3%3.6%6.8 $171.95

ALNY Short Interest - Frequently Asked Questions

Short interest is the volume of Alnylam Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of June 30th, traders have sold 5,799,788 shares of ALNY short. 4.38% of Alnylam Pharmaceuticals' shares are currently sold short. Learn More on Alnylam Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALNY shares currently have a short interest ratio of 4.2. Learn More on Alnylam Pharmaceuticals's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.38% of Alnylam Pharmaceuticals' floating shares are currently sold short.

Alnylam Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 5,799,788 shares, an increase of 6.7% from the previous total of 5,437,337 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

4.38% of Alnylam Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Alnylam Pharmaceuticals: Gilead Sciences, Inc. (2.06%), Vertex Pharmaceuticals Incorporated (1.95%), Regeneron Pharmaceuticals, Inc. (3.55%), Biogen Inc. (3.89%), United Therapeutics Corporation (5.46%), Incyte Corporation (6.32%), Neurocrine Biosciences, Inc. (5.77%), Exelixis, Inc. (11.66%), Ionis Pharmaceuticals, Inc. (10.74%), Madrigal Pharmaceuticals, Inc. (18.56%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($82.01 billion), Invesco QQQ ($47.15 billion), iShares Russell 2000 ETF ($24.07 billion), Nebius Group N.V. ($16.85 billion), Western Digital Corporation ($14.29 billion), SPDR S&P Biotech ETF ($11.89 billion), VanEck Semiconductor ETF ($11.29 billion), KLA Corporation ($10.37 billion), iShares 20+ Year Treasury Bond ETF ($8.78 billion), and Lumentum Holdings Inc. ($8.29 billion). View all of the most shorted stocks.

Short selling ALNY is an investing strategy that aims to generate trading profit from Alnylam Pharmaceuticals as its price is falling. ALNY shares are trading down $10.70 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Alnylam Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ALNY, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALNY, twice per month. The most recent reporting period available is June, 30 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like ALNY:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.



This page (NASDAQ:ALNY) was last updated on 7/10/2026 by MarketBeat.com Staff.
From Our Partners